Cargando…
Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first est...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534661/ https://www.ncbi.nlm.nih.gov/pubmed/34679613 http://dx.doi.org/10.3390/diagnostics11101915 |
_version_ | 1784587605308866560 |
---|---|
author | Šimánek, Václav Pecen, Ladislav Řezáčková, Hana Topolčan, Ondřej Fajfrlík, Karel Sedláček, Dalibor Šín, Robin Bludovská, Monika Pazdiora, Petr Slouka, David Kučera, Radek |
author_facet | Šimánek, Václav Pecen, Ladislav Řezáčková, Hana Topolčan, Ondřej Fajfrlík, Karel Sedláček, Dalibor Šín, Robin Bludovská, Monika Pazdiora, Petr Slouka, David Kučera, Radek |
author_sort | Šimánek, Václav |
collection | PubMed |
description | A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1–3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection. |
format | Online Article Text |
id | pubmed-8534661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85346612021-10-23 Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection Šimánek, Václav Pecen, Ladislav Řezáčková, Hana Topolčan, Ondřej Fajfrlík, Karel Sedláček, Dalibor Šín, Robin Bludovská, Monika Pazdiora, Petr Slouka, David Kučera, Radek Diagnostics (Basel) Article A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1–3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection. MDPI 2021-10-16 /pmc/articles/PMC8534661/ /pubmed/34679613 http://dx.doi.org/10.3390/diagnostics11101915 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Šimánek, Václav Pecen, Ladislav Řezáčková, Hana Topolčan, Ondřej Fajfrlík, Karel Sedláček, Dalibor Šín, Robin Bludovská, Monika Pazdiora, Petr Slouka, David Kučera, Radek Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title | Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title_full | Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title_fullStr | Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title_full_unstemmed | Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title_short | Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection |
title_sort | long-term monitoring of the antibody response to a sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534661/ https://www.ncbi.nlm.nih.gov/pubmed/34679613 http://dx.doi.org/10.3390/diagnostics11101915 |
work_keys_str_mv | AT simanekvaclav longtermmonitoringoftheantibodyresponsetoasarscov2infection AT pecenladislav longtermmonitoringoftheantibodyresponsetoasarscov2infection AT rezackovahana longtermmonitoringoftheantibodyresponsetoasarscov2infection AT topolcanondrej longtermmonitoringoftheantibodyresponsetoasarscov2infection AT fajfrlikkarel longtermmonitoringoftheantibodyresponsetoasarscov2infection AT sedlacekdalibor longtermmonitoringoftheantibodyresponsetoasarscov2infection AT sinrobin longtermmonitoringoftheantibodyresponsetoasarscov2infection AT bludovskamonika longtermmonitoringoftheantibodyresponsetoasarscov2infection AT pazdiorapetr longtermmonitoringoftheantibodyresponsetoasarscov2infection AT sloukadavid longtermmonitoringoftheantibodyresponsetoasarscov2infection AT kuceraradek longtermmonitoringoftheantibodyresponsetoasarscov2infection |